The first patient has been treated in everImmune’s Phase I clinical trial evaluating its oncobiotic drug candidate Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy of Oncobax AK when administered alongside an immunotherapy treatment. EverImmune plans to recruit a total of 60 patients […]
